PARD6A and rheumatoid arthritis: A high throughput screen of a library of FDA-approved drugs for compounds that disrupted the PB1 domain-mediated interaction between PKCι and Par6 identified several gold-containing compounds, used clinically for the treatment of rheumatoid arthritis [6].